Alison Dziarmaga, Vice President and U.S. Breast Cancer Franchise Head at AstraZeneca, ...

AstraZeneca (LSE:AZN) is advancing its oral GLP-1 candidate elecoglipron into Phase 3 trials after positive Phase 2b results.

The LinkedIn activities of AstraZeneca employees have yet again landed the drugmaker in hot water, with the U.K. marketing ...

AstraZeneca daily pill shows promising weight loss results in trial - ...

AstraZeneca’s experimental GLP-1 pill cut body weight by nearly 12% in obese patients over 36 weeks and reduced A1C, a metric ...

AstraZeneca CEO Pascal Soriot said AI is helping the company develop medicines faster and make smarter decisions throughout ...

AstraZeneca is emerging as a potential new contender in the booming obesity treatment market after its experimental ...

The Lung Cancer Research Foundation (LCRF), in collaboration with AstraZeneca, today announced that two research awards ...

A new GLP-1 oral medication from AstraZeneca, known as elecoglipron, lowered blood sugar levels and led to 10.5% weight loss ...

AstraZeneca Plc on Monday reported Phase 3 EMERALD-3 trial results showing that its immunotherapy-based STRIDE regimen, when ...

The approval relies on positive data from the POTOMAC Phase III trial.

The results were announced Monday in a conference in New Orleans.